相似文献
1
INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53.
Genes Dev. 1999 Oct 15;13(20):2670-7. doi: 10.1101/gad.13.20.2670.
2
Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis.
Genes Dev. 1999 Oct 15;13(20):2658-69. doi: 10.1101/gad.13.20.2658.
3
Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF.
Genes Dev. 1999 Oct 15;13(20):2678-90. doi: 10.1101/gad.13.20.2678.
4
INK4a/ARF locus alterations in human non-Hodgkin's lymphomas mainly occur in tumors with wild-type p53 gene.
Am J Pathol. 2000 Jun;156(6):1987-96. doi: 10.1016/S0002-9440(10)65071-7.
5
A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy.
Cell. 2002 May 3;109(3):335-46. doi: 10.1016/s0092-8674(02)00734-1.
6
INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas.
Oncogene. 2001 Oct 25;20(48):7104-9. doi: 10.1038/sj.onc.1204902.
7
p19(Arf) induces p53-dependent apoptosis during abelson virus-mediated pre-B cell transformation.
Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13194-9. doi: 10.1073/pnas.95.22.13194.
8
The role of Ink4a/Arf in ErbB2 mammary gland tumorigenesis.
Cancer Res. 2003 Jun 15;63(12):3395-402.
9
Loss of one allele of ARF rescues Mdm2 haploinsufficiency effects on apoptosis and lymphoma development.
Oncogene. 2004 Nov 25;23(55):8931-40. doi: 10.1038/sj.onc.1208052.
10
Obligate roles for p16(Ink4a) and p19(Arf)-p53 in the suppression of murine pancreatic neoplasia.
Mol Cell Biol. 2002 Jan;22(2):635-43. doi: 10.1128/MCB.22.2.635-643.2002.
引用本文的文献
1
Genome-wide in vivo CRISPR screens identify GATOR1 complex as a tumor suppressor in Myc-driven lymphoma.
Nat Commun. 2025 Aug 21;16(1):7582. doi: 10.1038/s41467-025-62615-y.
2
Bcl-xL is important for the antiapoptotic activity of Gfi1 and is upregulated by Gfi1 through hemgn.
J Immunol. 2025 May 1;214(5):1046-1058. doi: 10.1093/jimmun/vkae066.
3
Senescence-associated lineage-aberrant plasticity evokes T-cell-mediated tumor control.
Nat Commun. 2025 Mar 31;16(1):3079. doi: 10.1038/s41467-025-57429-x.
4
Advancing the genetic engineering toolbox by combining AsCas12a knock-in mice with ultra-compact screening.
Nat Commun. 2025 Jan 30;16(1):974. doi: 10.1038/s41467-025-56282-2.
5
Extra centrosomes delay DNA damage-driven tumorigenesis.
Sci Adv. 2024 Mar 29;10(13):eadk0564. doi: 10.1126/sciadv.adk0564.
6
Lymphoma dissemination is a pathological hallmark for malignant progression of B-cell lymphoma.
Front Immunol. 2023 Nov 22;14:1286411. doi: 10.3389/fimmu.2023.1286411. eCollection 2023.
7
Establishment of a primary renal lymphoma model and its clinical relevance.
Front Oncol. 2023 Aug 28;13:1089187. doi: 10.3389/fonc.2023.1089187. eCollection 2023.
8
MYC Oncogene: A Druggable Target for Treating Cancers with Natural Products.
Aging Dis. 2024 Apr 1;15(2):640-697. doi: 10.14336/AD.2023.0520.
9
MLL3 regulates the tumor suppressor locus in liver cancer.
Elife. 2023 Jun 1;12:e80854. doi: 10.7554/eLife.80854.
10
The Polyamine-Hypusine Circuit Controls an Oncogenic Translational Program Essential for Malignant Conversion in MYC-Driven Lymphoma.
Blood Cancer Discov. 2023 Jul 5;4(4):294-317. doi: 10.1158/2643-3230.BCD-22-0162.
本文引用的文献
1
Nucleolar Arf sequesters Mdm2 and activates p53.
Nat Cell Biol. 1999 May;1(1):20-6. doi: 10.1038/8991.
2
Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF.
Genes Dev. 1999 Oct 15;13(20):2678-90. doi: 10.1101/gad.13.20.2678.
3
Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis.
Genes Dev. 1999 Oct 15;13(20):2658-69. doi: 10.1101/gad.13.20.2658.
4
Disruption of p53 in human cancer cells alters the responses to therapeutic agents.
J Clin Invest. 1999 Aug;104(3):263-9. doi: 10.1172/JCI6863.
5
Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53.
Mol Cell. 1999 May;3(5):579-91. doi: 10.1016/s1097-2765(00)80351-2.
6
P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2.
Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6937-41. doi: 10.1073/pnas.96.12.6937.
7
Apoptosis and therapy.
J Pathol. 1999 Jan;187(1):127-37. doi: 10.1002/(SICI)1096-9896(199901)187:1<127::AID-PATH251>3.0.CO;2-T.
8
Apoptosis, p53, and tumor cell sensitivity to anticancer agents.
Cancer Res. 1999 Apr 1;59(7):1391-9.
9
Clinical implications of p53 mutations.
Cell Mol Life Sci. 1999 Jan;55(1):64-75. doi: 10.1007/s000180050270.
10
The p16INK4a/CDKN2A tumor suppressor and its relatives.
Biochim Biophys Acta. 1998 Oct 14;1378(2):F115-77. doi: 10.1016/s0304-419x(98)00017-1.
Zotero 插件